and joining you, thank us Thank today. for operator, you, everyone,
update very on are our third the progress provide quarter. an in to We pleased
call Bob initiatives provide update on and with of Chief Chief on our an key are strategic provide the who the our our to third I our Joining Officer; we Operating Ryan will product pipeline dimensions, quarter, Ryan a financial progress Dr. In growth, make session. our we and will strategic before will After Chief our excellence. handing the sustained today begin prepared development continued three an critically an Beechey, update. Financial update to with remarks, question-and-answer Scientific Phan, then third open line quarter performance. our and the Officer. call Bob, me on and for will a overview innovation important operational follow across
launch me on OvaWatch, efforts quarter. this an start confirming OvaWatch update innovation our in we that and with will Let today
fully several The of and code the Axia PLA go, November and is sales of CPT in signed submission including we Gynecology Chicago. Dr. the adopters, on unique Reilly applied Advisory of Committee Women’s Institute to for team ready and physicians a Gerard We have Dr. OvaWatch October, Nicole on Health, trained become Our and well for to respected early Williams reviewed X.
launch and New study York the we patients. New that will the our XXXX. this We this will in for validation. We approval which clinical York of to validation effective final or the stages manuscript payer publication adoption provider be laboratory notified requests, and to be and our processes are submitted been Kits waiting for X, related an approval have post-launch. study week. of are test regarding on April drive additional The and complete expect of to be We XXXX for by would completed OvaWatch tested state peer-review ready end believe to distribution
will offerings adnexal our broader to In physician decisions. experience their excited women, known clinical or of masses. positive their applicability and with OvaSuite. been and recognition have tests on provide chosen potential management confidence of the have be OvaWatch Healthcare access non-invasive will medical suite women We blood by receiving now providers of for population portfolio medicine to as practice change a feedback ovarian cancer with are a now together to of of unprecedented that the the
a OVERA women that provide time potentially pelvic or perform significant in mass meaningfully The population potential tool not. a beyond number first assess ordering healthcare also OvaSuite of OvaX the on oncologist, launch phase. that preventative identify whether gynecologist effectively to premature will our have now FDA-cleared provider will We who a opportunity unnecessary OvaX the an For patient of are This of surgery believe beyond is lifesaving female users who physician their the provide have to decided initial the and removal ever providers risk and information, primary OVERA patient expansion undergo has a and OvaWatch test. or an be opportunity the expand of of assessment. physicians that reduced, basis gynecological their to ovaries may malignancy an of and population are
women’s Following of practitioners. and family the health broadly other our be products launch more OvaWatch, to marketed OvaSuite will
said, medicine Care that clearly momentum published there refreshed in was strategy. available marketing an effective have Policy as Family Journal. OvaX and article of X, entitled Review to The the considerations family some ovarian updated and Mass, malignancy physicians In and With all youth, tool risk. and the identifies fact, On already cancer we by assessing for direction. our was that for family Primary physician Adnexal Practice July Management article a the Medicine
a our where spending more population. conferences, will can to to OvaSuite marketing we We high presentations impact of larger key physician launch shift at
have on This of launch Advisory implement our our Physician approaches of the in was developed just a our in is to marketing the programs pre-launch practices expect OvaWatch best of and We end Board as part snapshot year, that successful new field for physician which to strategy, plan territory. activities. the worked before formally most the based
we gross of operational timing now liquidity the of was capital excellence. million to small public this September, offering The Let’s our offering closed turn Starting and position. $X proceeds. In of with opportunistic.
of negotiate sustain plan. of to growth to attract the adequate I with along of provider with containment cost our ability million, cancer potential our critically year, EndoCheck. an company is commercial cash development impact the to important has provide and strategic and ovarian adoption on believe execution an this of or implementation the including which $X.X net efforts of commercial the suite and partners, Our of drive of to aggressive position will our OvaWatch part payer proceeds assessments, our our risk the campaign the launch of aggressive launch marketing strategy, and liquidity a development
capital our We and clear to have of runway we our I’m a we achieve have view the that confident initiatives. key need strategy,
and a top progress operational cash, of excellence, Moving priority. has utilization to our cash in usage innovation of been growth key managing of our another without aspect sacrificing
and quarter Farber Our in an this Cancer $X.X including for of endometriosis to was the payment cash million, $XXX,XXX testing payments. utilization portfolio Harvard’s our Institute severance $XXX,XXX Dana development
quarter. organization, moved we right we the for have a needs through our guidance. track the roles business of the on second people that half the year, then, cash organization, eliminating which reorganization we Throughout in the with was the time. look commercial with in at guidance and taking of focused very utilization of our our $XX team, reflect capacity. remain XXXX in on the Since in this We of $XX.X and first announced efforts excess that rest redundancy point Our started a and million ensuring the to we we have million, at close
are March being All of We X, when XX% taken year going believe related have our right things have $X other the we in will the will and team benefits million largely end finished that actions the since I and XXXX. the actions, headcount, into reduced payroll by became of related plus XXXX. expenses CEO. we in save payroll, I over cost with equal, the headcount this approximately of have we
for continue roles. we meet critical As hire and our key business to grows, we milestones, will
building are transparency and of when accountability culture, level a performance We every at the stresses organization. that
their the is sure goal person role in every our make understands in it. Our company and achieving to strategy
takes proud have have time, the of to this decisions despite are year. made we While retention, and this process difficult performance, work improve we employee staffing development the we done
to progress growth. our Turning and
a of same increase performed. achieved in with period XX% we quarter, XXXX. the volume over in million This a tests This $X.X X,XXX represents revenue,
As the year quarter companies the the over second diagnostic growth of from demonstrated with this to to volume quarter see as has volume well. X% Product was third second tend other the in sector, XXXX. increased been that case tapering we the
XXXX increased testing volume performed to second the to XX of Our in performed year. day day XX performed XX compared QX tests tests per XXXX quarter tests in the and in of last per per of third day quarter
OvaXPlus adding two a fourth back volume. highs we we’ve strong hit from everything performance, few including on we of daily for new incentives. first last to quarter fourth the quarter, We’re weeks And we are each Hurricane Ian, of weeks, impact seen the sales some And drive track. doing can
Looking collaboration to for partner for co-marketing of launch closing outcomes our distribution gap. with for BioReference and this improving at committed mission officially other a our we achievements quarter, and products. equity health OvaXPlus pleased growth shares Laboratories and health women, BioReference is were
optimistic With working potential the of Aspira the both are team sales about and we relationship. for trained together, long-term BioReference this and
gets a weeks as the commercial and on expect fourth started. in product ago, announced, As a quarter, volume few team reminder, we launched previously we the a only impact as small
themselves We are provide optimistic together intend that as grows. and experience our more guidance XXXX to working
including on transfer Finally, technology I relationship Health. an update with want to our our offerings, Women’s genetic provide Axia
than solution genetic attractive is executed screening our our low have to there quality was to when the signed deliver our Axia the agreements, genetics the physician we practices the marketplace it carrier players agreement. disclosed, changed carriers to we Developing before. far seen disruptions in Aspira previously Synergy genetic high has As more and agreement in-house massive tests an dramatically. carrier Since are less industry screening largest screening than was area, Even screening platform. intended available genetics ever
As a our capabilities, the of cease provided agreement. cancellation of result, testing and with to a Axia notice their of development their intent related of notified us us
the yet no in this As quarter. material cancellation platform impact not had financial launched, the had
provide drive of longer our and path carrier differentiated and genetic business, have highest see feel no is and difficult shareholders. resources improve This our will scale. close very it I that small believe made to or a Our cancellation and adoption the genetic strategic the future all away the product caused same and testing took genetic remains as from decision strong, Axia relationship September testing, cancellation XXXX. on will Aspira we directed Axia’s market developing for we the women to we the not offering screening or products the current return business forces business the offering. XX, a has on are impact walk better outcomes our GenetiX been I that Aspira discontinued contract the at will our achieve our do And Synergy. Accordingly, genetics part Synergy of Aspira a an look to effective to it, of of have products with considering
other better be customers, business. focused is launch As and you’ve both are for and including impacted. and adoption remains Synergy the year, for the make opportunities, launch of clear a of We’ve expect We of relationships need come commercial I to clear we have to a beginning we Synergy. eventually OvaWatch, will of heard care, women’s Synergy for that today, continuing labs our the But resulting we including do through envision XXXX critical the thing potential platform. cancer Aspira imminent tools as EndoCheck an much on are and since a Aspira regional women, that with tremendous the OvaXPlus number the changes offering want diagnostic organization. distribution of way EndoCheck. been ovarian and this through expected larger that OvaWatch one Aspira not our We long and
ourselves excellence. all operational position growth, for to we product We’re are success pipeline. me to Ryan on the our believe update on call development innovation With for mean necessary turn taking focused the over and steadfastly that, an are let steps
